30 December 2020
BSR's open to tenders for the contract to host, develop and manage the Biologics Register for Rheumatoid Arthritis (BSRBR-RA) from 1 January 2022 onwards.
The primary purpose of the register remains the same: tracking the progress of people in the UK with rheumatoid arthritis who have been prescribed biologic (including biosimilars) and other targeted therapies, compared to those not treated with these drugs.
Applications must be received by 5pm on 14 February 2021.
Applicant information